Clearpoint Neuro

CLPT · NASDAQ

$9.45+$0.28 (+3.05%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $9.17

CLPT analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $23.97 (+153.7% upside)

Low: $22.22
Now: $9.45
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

CLPT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
B. Riley Securities	Jun 18, 2026	Maintains	Buy	$20.00 → $30.00	53%
B. Riley Securities	Mar 18, 2026	Maintains	Buy	$18.00 → $20.00	32%
B. Riley Securities	Mar 5, 2026	Maintains	Buy	$28.00 → $18.00	32%

The case for and against

Updated Mar 27, 2026

Bull case

ClearPoint Neuro Inc. demonstrates a positive financial outlook, highlighted by a reported 17% growth in topline revenue and a significant reduction in cash burn for 2023. The company's strategic expansion in partnerships, particularly within the biologics segment, is expected to drive at least 20% revenue growth in 2024, further enhancing its financial performance. Additionally, the progress made in product approvals and system installations, supported by favorable clinical publications, reinforces the company's momentum heading into 2024, suggesting a strong trajectory for sustained growth and improved profitability.

Bear case

ClearPoint Neuro has demonstrated a significant reduction in cash burn throughout 2023, decreasing from $5.8 million in the first quarter to $1.2 million in the fourth quarter, indicating improved financial management. However, despite the positive trend in cash burn, the company operates in a competitive market with uncertainty regarding its ability to scale its integrated systems effectively amid potential industry challenges. Furthermore, without sustained revenue growth from both its medical device segment and its biologics partnerships, the long-term financial viability of ClearPoint Neuro remains questionable, warranting a cautious outlook on its stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.